Low vitamin B12 is not automatically pernicious anemia. The distinction matters because autoimmune loss of intrinsic factor usually means lifelong replacement and a different follow-up plan.
- Intrinsic factor antibody positivity is highly specific for pernicious anemia, but only about 40-60% of affected people test positive.
- Parietal cell antibodies are more sensitive, often present in 80-90% of autoimmune gastritis cases, but are less specific than intrinsic-factor antibodies.
- Vitamin B12 below 148 pmol/L (200 pg/mL) supports deficiency; 148-300 pmol/L is a diagnostic grey zone where MMA or homocysteine can help.
- Methylmalonic acid above about 0.40 µmol/L supports cellular B12 deficiency, although reduced kidney function can raise it independently.
- Pernicious anemia symptoms can include fatigue, glossitis, tingling, imbalance, memory change, low mood, and breathlessness—even before anemia develops.
- A normal MCV does not exclude B12 deficiency because iron deficiency, inflammation, or thalassemia trait can mask macrocytosis.
- Confirmed autoimmune B12 malabsorption usually requires lifelong B12 replacement; dietary deficiency may resolve after dietary correction and a limited treatment course.
- New pernicious anemia warrants consideration of upper endoscopy because it is a late manifestation of autoimmune atrophic gastritis.
Which symptoms make pernicious anemia likely—and what confirms it?
Pernicious anemia is confirmed most convincingly when vitamin B12 deficiency occurs with a positive intrinsic-factor antibody test; parietal cell antibodies support autoimmune gastritis but cannot confirm it alone. Symptoms range from tiredness and a sore tongue to pins-and-needles, poor balance, or cognitive slowing, and nerve symptoms can occur with a normal haemoglobin. In my clinical work, that last point is where delays happen.
Pernicious anemia symptoms often develop gradually over months or years because liver B12 stores can last 2-5 years. Breathlessness on stairs, palpitations, pale skin, mouth ulcers, a smooth red tongue, numb feet, altered vibration sense, and an unsteady gait are useful clues; none is diagnostic on its own. Vitamin B12 reference ranges help put a reported value into laboratory context.
A positive intrinsic-factor antibody in a person with biochemical B12 deficiency usually establishes autoimmune B12 malabsorption. In contrast, a low B12 level in a strict vegan, someone taking metformin, or a patient with coeliac disease does not automatically mean pernicious anemia. Dr. Thomas Klein has seen patients treated for years with injections before anyone established whether the cause was permanent.
Kantesti AI is an AI blood test analyzer that identifies the clinically meaningful cluster of low B12, rising MCV, elevated MMA, and autoimmune clues rather than treating one abnormal number as a diagnosis. That pattern-based approach is useful, but no app can replace a clinician's neurological examination or a properly targeted antibody test.
Symptoms that should prompt urgent assessment
New difficulty walking, rapidly worsening numbness, confusion, visual change, or severe shortness of breath needs prompt medical assessment rather than a wait-and-see supplement trial. Neurological injury from B12 deficiency can become only partly reversible when treatment is delayed beyond several months.
Why autoimmune B12 malabsorption differs from dietary deficiency
Pernicious anemia results from autoimmune gastritis that damages acid-producing parietal cells and removes intrinsic factor, the stomach protein needed for efficient ileal B12 absorption. Dietary deficiency means the absorption mechanism is intact but the supply is too low.
Only about 1% of a large oral B12 dose can enter by passive diffusion without intrinsic factor. That small route explains why 1,000-2,000 micrograms of oral cyanocobalamin can work for many people with pernicious anemia, while ordinary food amounts cannot. The CBC pattern is easier to interpret alongside our guide to MCV and MCH.
Dietary B12 deficiency is most common in people avoiding all animal-derived foods without fortified foods or supplements, but it also occurs with food insecurity and restrictive eating. A person who improves after correcting intake may not need lifelong injections; a person with intrinsic-factor failure generally does. This distinction is practical, not semantic.
Autoimmune gastritis can produce iron deficiency years before B12 deficiency because reduced stomach acid impairs non-haem iron absorption. I become more suspicious when a patient has unexplained low ferritin in their forties, followed later by macrocytosis or falling B12—particularly if thyroid autoimmunity is also present.
Why food history still matters
A diet history changes the pre-test probability but does not overrule antibodies. A vegan can develop pernicious anemia, and a meat-eater can have simple low intake, so clinicians should avoid assuming cause from diet alone.
Who should have an intrinsic-factor antibody test?
Intrinsic-factor antibody testing is most useful when B12 deficiency is established or strongly suspected and the cause is not obvious. It is especially reasonable with macrocytosis, neuropathy, autoimmune thyroid disease, vitiligo, type 1 diabetes, unexplained iron deficiency, or a family history of autoimmune disease.
Testing every person with a B12 level of 280 pmol/L is usually low yield. I would first check supplement use, diet, full blood count, folate, kidney function, and—when needed—MMA; then order antibodies when the clinical picture still points to impaired absorption. Our 15,000-plus biomarker guide explains why test names and units differ between laboratories.
Neurological symptoms lower the threshold for testing and treatment. A 46-year-old office worker with B12 of 235 pmol/L, normal haemoglobin, and progressively numb toes deserves more attention than a symptom-free person with the same result after starting a multivitamin 48 hours earlier.
Family clustering is real but not deterministic. First-degree relatives do not need blanket antibody screening, yet a relative with fatigue, iron deficiency, or autoimmune thyroid disease should mention the family history when discussing B12 testing.
When not to wait for the result
Severe neurological symptoms or marked megaloblastic anemia justify starting B12 replacement immediately after diagnostic samples are drawn. Treatment should not be delayed for an antibody result that may take days.
The blood tests that establish true B12 deficiency
Serum B12 below 148 pmol/L (200 pg/mL) generally supports deficiency, while results from 148-300 pmol/L require clinical context and often MMA or homocysteine. A single B12 value is a screening result, not a complete explanation of cause.
MMA rises when cells cannot use B12 for methylmalonyl-CoA metabolism, often before anemia is visible. A value above roughly 0.40 µmol/L supports B12 deficiency, but chronic kidney disease can elevate MMA even when B12 status is adequate; MMA interpretation is never a kidney-free calculation.
Homocysteine above 15 µmol/L can support B12 deficiency but is less specific because folate deficiency, B6 deficiency, hypothyroidism, smoking, and reduced eGFR can also raise it. A normal MMA with high homocysteine should make me look carefully at folate, renal function, and thyroid status.
Kantesti is an AI blood test interpretation platform that reads B12 alongside creatinine, MCV, RDW, folate, and prior results to flag when a borderline value has a more concerning pattern. Results should still be reviewed with the ordering clinician, particularly before treatment alters the baseline.
Active B12 can be helpful, but is not universal
Holotranscobalamin below about 25 pmol/L suggests depleted biologically available B12 in laboratories using that assay. It can be useful early in deficiency, although local reference intervals and availability vary; see active B12 testing.
How to interpret a positive or negative intrinsic-factor antibody test
A positive intrinsic-factor antibody test is highly specific for pernicious anemia, whereas a negative result does not rule it out. Depending on assay and population, sensitivity is commonly only 40-60%, so many genuinely affected patients are antibody-negative.
Intrinsic-factor antibodies may block B12 binding or prevent the intrinsic-factor-B12 complex from attaching to ileal receptors. Laboratories report the result qualitatively in many countries, so a “positive” result carries more clinical weight than a marginal numerical level.
The test is best drawn before B12 therapy when feasible, but treatment should never be withheld for the sake of cleaner diagnostics. Some assays can be affected by recent B12 injection or by high circulating B12, and laboratories differ in their handling of these interferences.
A positive test without low B12 may identify early autoimmune gastritis, but it does not automatically prove active pernicious anemia. I usually repeat nutritional markers, assess symptoms, and discuss gastric evaluation rather than label a well person on antibodies alone.
The false-negative problem
Negative intrinsic-factor antibodies leave autoimmune gastritis on the table when parietal cell antibodies, high gastrin, low pepsinogen I, iron deficiency, and compatible biopsy findings converge. A negative result should narrow the diagnosis, not close it.
What parietal cell antibodies can—and cannot—tell you
Parietal cell antibodies support autoimmune gastritis but are not specific enough to diagnose pernicious anemia by themselves. They are detected in roughly 80-90% of established autoimmune gastritis cases, yet can occur in autoimmune thyroid disease, type 1 diabetes, and some healthy older adults.
Parietal cell antibodies target the gastric proton pump, usually the H+/K+-ATPase on acid-producing cells. Their presence makes the autoimmune route more plausible, especially with low B12 or iron stores, but the positive predictive value falls sharply in low-risk people.
Age changes interpretation. Low-level positivity is more common after age 60, so a 68-year-old with normal haemoglobin, B12 of 390 pmol/L, and no gastric markers should not be told they have pernicious anemia from this finding alone; thyroid antibody context offers a useful parallel.
The combination of positive parietal cell antibodies and positive intrinsic-factor antibodies is much more persuasive than either isolated result. When the two tests disagree, I give intrinsic-factor positivity greater diagnostic weight and use gastric biomarkers or endoscopy to settle the rest.
A common misunderstanding
Parietal cell antibodies do not measure stomach acid and do not show the degree of gastric damage. They indicate immune recognition; gastrin, pepsinogen, iron indices, and biopsy provide different information.
What to do when antibody results and B12 levels disagree
Discordant results are common: positive antibodies can precede deficiency, and negative antibodies can occur in established autoimmune gastritis. The next step is to reconcile the physiology rather than repeat the same test without a question.
Positive parietal cell antibodies with normal B12 often merit fasting gastrin, pepsinogen I or pepsinogen I/II ratio, iron studies, and periodic B12 follow-up—not immediate lifelong injections. Proton-pump inhibitors can raise gastrin substantially, so medication history must be recorded before interpreting it.
Low B12 with both antibodies negative should prompt a search for dietary restriction, coeliac disease, ileal disease or resection, pancreatic insufficiency, nitrous oxide exposure, metformin, and acid suppression. Total IgA should accompany coeliac serology because low IgA can make a standard tTG-IgA result falsely reassuring.
The 2014 British guideline by Devalia et al. advises using clinical features and second-line metabolites when serum B12 is uncertain, rather than relying on one assay. That remains sensible in 2026: laboratory medicine is unusually vulnerable here to supplements, timing, and assay design.
When endoscopy becomes the clarifier
Upper endoscopy with systematic stomach biopsies can confirm corpus-predominant atrophic gastritis and exclude alternative gastric pathology. It is generally a gastroenterology decision, not a routine first test for every borderline B12 result.
Why a normal MCV does not rule out pernicious anemia
A normal mean corpuscular volume does not exclude B12 deficiency or pernicious anemia. Macrocytosis can be masked by iron deficiency, chronic inflammation, thalassemia trait, or recent blood loss, producing a deceptively average MCV.
An MCV above 100 fL raises suspicion for B12 or folate deficiency, alcohol exposure, liver disease, hypothyroidism, reticulocytosis, or marrow disorders, but it is neither sensitive nor specific. I pay close attention to RDW because a rising value may reveal mixed cell populations before the MCV shifts.
Iron deficiency and B12 deficiency can coexist in autoimmune gastritis, creating normal MCV values such as 88-94 fL despite meaningful deficiency. The relevant question is not “is MCV normal?” but “do haemoglobin, ferritin, RDW, smear, B12, and symptoms fit together?” RDW and red-cell indices are useful for this mixed-pattern problem.
A low reticulocyte count in anemia suggests inadequate marrow production, whereas a rising reticulocyte count about 5-10 days after B12 treatment supports an appropriate response. Reticulocytes can be blunted when iron is also depleted.
Macrocytosis has important alternatives
Persistent macrocytosis with normal B12, folate, thyroid tests, and liver tests may need a blood-film review and haematology assessment. Pernicious anemia is common enough to test for, but it should not become a catch-all diagnosis.
Medicines, gut conditions, and exposures that mimic pernicious anemia
Metformin, long-term acid suppression, coeliac disease, Crohn's disease affecting the terminal ileum, gastric surgery, and nitrous oxide exposure can cause B12 deficiency without pernicious anemia. Antibody tests distinguish autoimmune gastric failure from many of these alternatives.
Metformin-associated B12 deficiency becomes more likely with higher dose and longer duration, and it may appear after several years of treatment. The MHRA advised in 2022 that B12 should be checked in metformin users with anemia or neuropathy; our guide to blood work after metformin explains related monitoring.
Proton-pump inhibitors reduce release of food-bound B12 by lowering gastric acidity, but they do not usually eliminate intrinsic factor. This means an affected patient may respond to oral replacement and medication review, unlike someone whose autoimmune gastritis has destroyed intrinsic-factor production.
Nitrous oxide irreversibly inactivates functional B12 and can trigger neurological injury even when serum B12 is in the laboratory range. In that setting, MMA and homocysteine may be more revealing than total B12, and urgent specialist assessment is appropriate for gait or sensory changes.
Do not overlook coexisting causes
A person can have pernicious anemia and a second contributor such as metformin use or coeliac disease. Finding one plausible explanation should not stop an investigation when the laboratory response is unexpectedly poor.
When confirming pernicious anemia changes long-term treatment
Confirmed pernicious anemia usually changes B12 treatment from a temporary correction plan to lifelong replacement and gastric follow-up. Dietary deficiency may be treated with dietary change plus oral B12, then reassessed after stores and symptoms recover.
In UK practice, hydroxocobalamin 1 mg intramuscularly is commonly given frequently during loading, then every 2-3 months for maintenance; neurological involvement often uses a more intensive initial schedule. Regimens vary by country, formulation, and symptom severity, so patients should follow the prescriber's protocol rather than copy an online timetable.
High-dose oral cyanocobalamin, commonly 1,000-2,000 micrograms daily, can maintain many people through passive absorption even without intrinsic factor. The evidence supports oral therapy for selected adherent patients, but injections remain sensible when symptoms are neurological, adherence is uncertain, or response needs to be assured quickly. NICE guideline NG239, published in 2024, supports cause-based replacement decisions.
Methylcobalamin is not proven superior to cyanocobalamin or hydroxocobalamin for most patients with pernicious anemia. Formulation matters less than dose, consistency, cause, and follow-up; compare methylated B12 and cyanocobalamin before paying a premium for marketing claims.
Folate should not be given alone
Folic acid can improve megaloblastic anemia while neurological B12 injury continues, so B12 status must be assessed before treating presumed folate deficiency alone. Combined deficiency is possible, but B12 replacement should not be delayed.
How to monitor response after B12 treatment begins
A successful response usually includes improved reticulocytes within 5-10 days, rising haemoglobin over 2-4 weeks, and falling MMA or homocysteine when they were elevated. Tingling, gait instability, and cognitive symptoms recover more variably and can take 6-12 months.
A serum B12 level becomes a poor marker of treatment adequacy soon after an injection because it can rise dramatically regardless of tissue recovery. I monitor symptoms, full blood count, reticulocytes when anemia is present, and functional markers selectively rather than chasing a very high serum B12.
Failure of haemoglobin to improve by 4-8 weeks should trigger a search for iron deficiency, folate deficiency, ongoing blood loss, renal disease, inflammation, marrow disease, or an incorrect diagnosis. A longitudinal lab comparison is often more informative than a single “normal” follow-up result.
Kantesti AI can organize serial B12, MCV, haemoglobin, ferritin, creatinine, and MMA results so that slow improvement or an unexpected reversal is visible. In my experience, patients who save the dose dates beside their results avoid many needless arguments about whether a changing B12 level means treatment failed.
Neurological recovery is not a stopwatch
Persistent numbness after treatment does not prove that B12 was unrelated, especially when symptoms were present for more than 6 months before therapy. Diabetes, spinal disease, alcohol use, and B6 excess can coexist and deserve separate assessment.
Why pernicious anemia can change stomach and autoimmune follow-up
Pernicious anemia is a late manifestation of autoimmune atrophic gastritis, which is why confirmation can justify gastroenterology review even after B12 levels normalize. The concern is not that every patient has cancer; it is that chronic corpus-predominant atrophy changes long-term risk.
The American Gastroenterological Association advises endoscopy with topographical biopsies for patients with a new diagnosis of pernicious anemia who have not recently had an upper endoscopy. Shah et al. (2021) frame this as risk stratification for atrophic gastritis and prevalent gastric neoplasia, not a reason for panic.
Autoimmune gastritis is associated with increased risk of gastric adenocarcinoma and type 1 gastric neuroendocrine tumors, although individual risk varies with histology, age, smoking, H. pylori status, and family history. Surveillance intervals are individualized; there is no single annual-endoscopy rule for every patient.
Thyroid disease is the autoimmune partner I look for most often, followed by type 1 diabetes, vitiligo, and occasionally Addison disease. Kantesti's clinical methodology follows pattern-based checks rather than diagnosis-by-algorithm; readers can review our medical validation approach and take a concise history to their clinician.
Ask about H. pylori separately
H. pylori can cause atrophic gastritis and may coexist with autoimmune disease, but it is not interchangeable with pernicious anemia. Testing and eradication decisions depend on local practice and endoscopic findings.
Special situations: pregnancy, older age, vegan diets, and kidney disease
Pregnancy, older age, plant-based diets, and reduced kidney function all complicate B12 interpretation, but none changes the fundamental meaning of a positive intrinsic-factor antibody. The antibody identifies autoimmune risk; metabolites and symptoms require more tailoring.
Pregnancy can lower total B12 through changes in binding proteins and plasma volume, so borderline results need careful interpretation with symptoms, diet, and functional markers. Neurological symptoms or anemia during pregnancy deserve prompt obstetric and medical assessment; see our pregnancy supplement guide.
In older adults, impaired food-B12 release from low acid, medication use, and autoimmune gastritis are all more common. Parietal cell antibody positivity alone is less specific after age 60, which is one reason intrinsic-factor antibodies and gastric context matter so much.
eGFR below 60 mL/min/1.73 m² can elevate MMA independently of B12 status. In a patient with chronic kidney disease, an elevated MMA should support—not replace—clinical judgement, B12 results, and antibody testing.
A vegan diet does not exclude pernicious anemia
A vegan with a positive intrinsic-factor antibody still has autoimmune B12 malabsorption, even if low dietary intake also contributed. Dietary change remains healthy and necessary, but it does not restore intrinsic factor.
How to read a pernicious anemia lab report without overdiagnosing yourself
The safest interpretation combines symptoms, B12 status, functional markers, complete blood count, antibodies, medications, and prior results. A flagged antibody or a low-normal B12 alone is a reason for a conversation, not a final diagnosis.
Before interpreting results, write down the exact B12 product, dose, route, and date of the last dose. A 1,000-microgram oral tablet or recent injection can alter serum B12 and make an otherwise useful baseline much harder to read; result-review timing matters.
Kantesti is an AI-powered blood test analysis tool that can extract values from laboratory PDFs and compare current markers with prior panels in about 60 seconds. It should be used to prepare informed questions—such as whether a negative intrinsic-factor antibody was paired with MMA, ferritin, renal function, and gastric markers—not to self-prescribe injections.
Dr. Thomas Klein recommends bringing a one-page timeline of symptoms, diet change, gastric surgery, autoimmune diagnoses, medicines, and every B12 treatment date. Clinicians make faster, safer decisions when the timeline explains why a serum level rose or why neuropathy preceded anemia.
The one-result trap
An out-of-range laboratory flag reflects that laboratory's statistical interval, not the probability of pernicious anemia. Compare the result with the lab's units and method before applying an internet cutoff.
Questions to ask your clinician and the evidence behind this approach
Ask whether your B12 deficiency is confirmed, whether intrinsic-factor and parietal cell antibodies were measured, and whether the cause is temporary or lifelong. If pernicious anemia is likely, also ask whether iron studies, thyroid testing, and gastroenterology assessment are appropriate.
Useful questions include: “Was my sample taken before treatment?”, “Could my kidney function distort MMA?”, and “What would make you recommend endoscopy?” These questions are more productive than asking whether a single number is “bad.” Our physician reviewers are described on the Medical Advisory Board page, including how medical oversight informs educational content.
As of July 30, 2026, the clinical evidence still supports a cause-first approach: treat established or strongly suspected deficiency promptly, then determine whether intrinsic-factor failure makes treatment lifelong. The 2024 NICE guideline and the AGA update by Shah et al. (2021) are consistent on the value of connecting laboratory findings to symptoms and gastric disease.
For methodological background only—not evidence that diagnoses pernicious anemia—Kantesti Research Team. (2026). _aPTT Normal Range: D-Dimer, Protein C Blood Clotting Guide_. Zenodo. DOI. ResearchGate record. Academia.edu record.
For laboratory-context background only, Kantesti Research Team. (2026). _Serum Proteins Guide: Globulins, Albumin & A/G Ratio Blood Test_. Zenodo. DOI. ResearchGate record. Academia.edu record.
A practical next step
If you have progressive neurological symptoms, severe anemia, or a confirmed low B12 result, arrange clinician review promptly and do not wait for an online interpretation alone. The most useful outcome is a documented cause and a treatment plan you can maintain.
Frequently Asked Questions
Can you have pernicious anemia with negative intrinsic factor antibodies?
Yes. Intrinsic-factor antibodies are highly specific but are detected in only about 40-60% of people with pernicious anemia, so a negative result does not exclude autoimmune gastritis. When suspicion remains high, clinicians combine parietal cell antibodies, B12, MMA, iron studies, fasting gastrin, pepsinogen markers, and sometimes upper endoscopy. A negative antibody result should trigger a cause review rather than automatically lead to a dietary-deficiency diagnosis.
What antibody test confirms pernicious anemia?
A positive intrinsic-factor antibody test is the most specific blood-test evidence for pernicious anemia, particularly when vitamin B12 is below 148 pmol/L (200 pg/mL) or MMA is elevated. Parietal cell antibodies support autoimmune gastritis but are less specific because they can occur with thyroid autoimmunity and in some healthy older adults. The strongest laboratory pattern is B12 deficiency plus positive intrinsic-factor antibodies, with or without positive parietal cell antibodies.
Can pernicious anemia cause symptoms when the CBC is normal?
Yes. Pernicious anemia can cause tingling, numbness, balance change, cognitive slowing, glossitis, or fatigue before haemoglobin falls or MCV rises above 100 fL. A normal CBC does not exclude tissue B12 deficiency, especially when iron deficiency or inflammation masks macrocytosis. Borderline serum B12 values of 148-300 pmol/L should be assessed with symptoms and often MMA or homocysteine.
Do I need B12 injections for life if I have pernicious anemia?
Most people with confirmed pernicious anemia need lifelong vitamin B12 replacement because intrinsic-factor production does not reliably recover. Maintenance treatment commonly uses hydroxocobalamin 1 mg by injection every 2-3 months in UK practice, although schedules differ internationally. High-dose oral B12 of 1,000-2,000 micrograms daily can work for selected adherent patients through passive absorption, but the choice should be individualized with a clinician.
What is the difference between low B12 and pernicious anemia?
Low B12 is a laboratory finding or nutrient deficiency, while pernicious anemia is a specific autoimmune cause of B12 malabsorption caused by loss of intrinsic factor. Dietary restriction, metformin, proton-pump inhibitors, coeliac disease, ileal disease, and gastric surgery can all lower B12 without pernicious anemia. Identifying the cause determines whether treatment may be temporary or needs to continue for life.
Can high vitamin B12 after an injection rule out pernicious anemia?
No. Serum B12 can become very high after an injection or high-dose supplement even when the underlying problem is permanent autoimmune malabsorption. A post-treatment B12 level does not prove that intrinsic factor is functioning or that treatment can stop. Antibody results, pre-treatment values, symptoms, and the documented cause are more useful for deciding whether long-term replacement is needed.
Get AI-Powered Blood Test Analysis Today
Join over 2 million users worldwide who trust Kantesti for instant, accurate lab test analysis. Upload your blood test results and receive comprehensive interpretation of 15,000+ biomarkers in seconds.
📚 Referenced Research Publications
Klein, T., Mitchell, S., & Weber, H. (2026). aPTT Normal Range: D-Dimer, Protein C Blood Clotting Guide. Kantesti AI Medical Research.
Klein, T., Mitchell, S., & Weber, H. (2026). Serum Proteins Guide: Globulins, Albumin & A/G Ratio Blood Test. Kantesti AI Medical Research.
📖 External Medical References
National Institute for Health and Care Excellence (2024). Vitamin B12 deficiency in over 16s: diagnosis and management. NICE Guideline NG239.
⚕️ Medical Disclaimer
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment decisions.
E-E-A-T Trust Signals
Experience
Physician-led clinical review of lab interpretation workflows.
Expertise
Laboratory medicine focus on how biomarkers behave in clinical context.
Authoritativeness
Written by Dr. Thomas Klein with review by Dr. Sarah Mitchell and Prof. Dr. Hans Weber.
Trustworthiness
Evidence-based interpretation with clear follow-up pathways to reduce alarm.